WO2015197892A1 - Composición que contiene ácido fítico, magnesio y polifenoles para el tratamiento o la prevención de la litiasis renal - Google Patents
Composición que contiene ácido fítico, magnesio y polifenoles para el tratamiento o la prevención de la litiasis renal Download PDFInfo
- Publication number
- WO2015197892A1 WO2015197892A1 PCT/ES2015/070296 ES2015070296W WO2015197892A1 WO 2015197892 A1 WO2015197892 A1 WO 2015197892A1 ES 2015070296 W ES2015070296 W ES 2015070296W WO 2015197892 A1 WO2015197892 A1 WO 2015197892A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- magnesium
- composition according
- calcium
- composition
- phytate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to a composition
- a composition comprising phytic acid or any of its salts of phytate, magnesium and optionally polyphenols, which is useful for the treatment of renal lithiasis, mainly calcium calcium lithiasis, for the synergy between its components to inhibit the crystallization of calcium salts, the decrease of free oxalate and papillary lesions due to oxidative stress.
- the present invention belongs to the field of pharmacology.
- phytates phytic acid ionic species
- phytates have the capacity to inhibit the development of calcium salt deposits in biological fluids, thus reducing the risk of developing both calcium kidney stones and other pathological calcifications.
- phytate which is found in mammalian tissues and fluids, comes primarily from the diet.
- renal stones of calcium oxalate papillary monohydrate occur as a result of lesions that originate in the tissue of the renal papilla (F Grases, A Costa-Bauza, RM Prieto, A Conté, A Servera, BMC Urol , 2013, 13:14, doi: 10.1 186/1471-2490-13-14).
- Calcium oxalate stones represent approximately 70% of kidney stones, with the level of urinary oxalate being an important risk factor for its development.
- the control of free oxalate in urine is a very important aspect in the treatment against the development of calcium oxalate stones.
- magnesium by forming soluble complexes with the oxalate ion, significantly decreases the supersaturation of calcium oxalate, which translates into an increase in its difficulty in generating calcium oxalate crystals.
- the present invention aims at presenting new formulas for the treatment of renal lithiasis, preferably calcium renal lithiasis, related to the aspects described in the state of the art section and with recent discoveries on the combination of phytic acid and / or their pharmaceutically acceptable phytates with polyphenols and magnesium salts.
- This combination can be very beneficial for the treatment of kidney stones, preferably calcium kidney stones, and more preferably calcium oxalate, since the inhibitory capacity of calcium salt crystallization by phytate adds to the beneficial effect of polyphenols. papillary lesions from oxidative stress.
- a first aspect of the present invention relates to a composition comprising phytic acid or any of its salts, which may be in isolated form or in the form of an enriched plant extract, and magnesium in the form of a hydroxide or oxide salt.
- calcifications includes all processes or conditions that involve / induce the formation of solid precipitates in the urine.
- conditions that induce renal calculi or calculi include, but are not limited to a high level of urinary oxalate, a high level of urinary excretion of calcium or a reduced presence or activity of nucleation and crystalline growth inhibitors.
- Urine oxalate refers to the excretion of oxalate in the urine. Normal levels between 8-30 mg / day are considered, while if these exceed 45mg / day it is considered a situation of hyperoxaluria. Urine oxalate levels can reach levels between 90 and 270mg / day in patients with primary hyperoxaluria.
- “Hypercalciuria” refers to a high urinary excretion of calcium which exceeds 300mg / day or 4mg / kg / day.
- the "reduced presence or activity of inhibitors of nucleation and growth of crystalline solids” refers to all those compounds that they can modulate said process, which include but are not limited to glycoproteins such as nephrocalcin or osteopontin and certain inorganic and organic polyphosphates. These compounds interact with the crystals and inhibit their growth.
- phytic acid or "myo-inositol-hexaphosphate” means the molecule of formula:
- phytate is the form of phytic acid in which at least one hydrogen has been lost so that the corresponding phosphate group interacts with a cation (K, Mg, Ca, Mn, Zn and Fe).
- the phytate salts of interest in the invention are mainly sodium, potassium, calcium, magnesium, zinc and calcium magnesium salts.
- the composition of the invention comprises at least one polyphenol.
- polyphenols means a group of chemical substances found in plants characterized by the presence of more than one phenol group per molecule. These products have important antioxidant characteristics and are also suitable for human consumption.
- the polyphenols with special interest for the composition of the invention are those extracted from the seeds of red grape or white grape, although they can come from other plant species such as berries, tea, beer, olive oil, chocolate / cocoa, nuts, pomegranates etc. .
- Concrete examples of preferred polyphenols of the invention are epicatechin, catechin, gallocatechin, epigallocatechin, quercetin, resveratrol, tannic acid or gallic acid.
- Magnesium by forming salts more soluble than calcium with phytate, increases the absorption of phytate at the intestinal level, which results in an increase in phytate excreted in the urine and therefore in an increase in its inhibitory capacity against formation of kidney stones of calcium oxalate.
- a formulation comprising phytate in a form that also contains polyphenols and / or salts or magnesium oxide, can be used for the manufacture of medicaments or dietary supplements intended for the treatment or prophylaxis of renal lithiasis, preferably calcium, and more preferably oxaloccalcic.
- phytic acid and / or its pharmaceutically acceptable salts may be used freely as pure substances, extracts of plant species containing them, such as, for example, extracts of white or brown rice, or vehicular transported in species vegetables that contain them, such as germs or external parts of the grains or fruits of wheat, oats, soybeans, almonds, garrof ⁇ n, etc.
- Polyphenols can also be used freely as pure substances or as extracts of plant species that contain them or that are pharmaceutically acceptable.
- Magnesium can be supplied in the form of its pharmaceutically acceptable salts such as magnesium oxide, magnesium hydroxide, magnesium citrate, magnesium stearate, magnesium carbonate, magnesium chloride and magnesium sulfate.
- the composition of the invention comprises between 40 and 50% by weight of phytic acid or its salts.
- the composition of the invention comprises between 25 and 40% by weight of magnesium in the form of salt, hydroxide or oxide.
- composition of the invention between 10-30% by weight of polyphenols.
- Another aspect of the invention relates to the use of the composition of the invention for the manufacture of a medicament.
- Another aspect of the invention relates to the use of the composition described for the manufacture of a medicament for the treatment of renal lithiasis.
- the renal lithiasis is calcium renal lithiasis.
- Another aspect of the invention relates to the use of the composition of the invention for the preparation of a medicament intended to reduce risks and improve the health status of patients with diseases related to the crystallization of calcium oxalate.
- a very important advantage of using the combination of phytate, polyphenols and magnesium is that the action of a crystallization inhibitor is combined.
- the combination of phytate, polyphenols and magnesium can be administered in solid form (including granules, powder or suppositories) or in liquid form (such as solutions, suspensions or emulsions). In turn, they can be administered as such or, after being subjected to operations such as sterilization, preservative addition, stabilizer addition or emulsifier addition.
- phytate, polyphenols and magnesium may be combined with one or more compounds that facilitate its absorption through the selected route of administration.
- they can be administered with lactose, sucrose, talc, magnesium stearate, cellulose, calcium salts, gelatin, fatty acids, as well as with other pharmaceutically acceptable substances.
- Pharmaceutical compositions containing phytate, polyphenols and magnesium will include an amount of each active ingredient that effectively reduces urinary oxalate levels.
- the effective amounts for this purpose depend on factors such as the route of administration, the health of the individual or urinary levels of oxalate, although these factors do not limit the inclusion of others that help define the recommended amounts.
- the amounts of each active ingredient that each individual will take will be determined by a specialist based on each individual circumstance.
- the composition is in a dose suitable for administration between 500 mg / day and 1,000 mg / day.
- the term "renal lithiasis”, “urolithiasis” or “nephrolithiasis” refers to the disorder caused by the presence of stones or stones inside the kidneys or urinary tract (ureters, bladder). Kidney stones are made up of normal urine substances (calcium salts, uric acid, cystine etc.) that for different reasons have been concentrated and precipitated forming fragments of greater or lesser size.
- uric acid crystals or "uric acid stones” includes all those processes or conditions that involve / induce the formation of solid precipitates in the urine in which this substance is involved.
- the composition is a pharmaceutical composition or a nutraceutical or functional food.
- nutraceutical or “functional food”
- the nutraceutical term can be applied to extracts or chemical compounds obtained from common foods. Examples of foods to which nutraceutical properties are attributed are olive oil, red wine, broccoli, soybeans, etc.
- Nutraceuticals are normally used in nutritional mixtures and in the pharmaceutical industry. In the same way that some foods can be classified as nutraceuticals, they also classify some nutritional supplements, such as fatty acids such as omega-3 derived from fish oil and some vegetables or antioxidants and vitamins.
- compositions are the adjuvants and vehicles known to those skilled in the art and commonly used in the elaboration of therapeutic compositions.
- word "comprises” and its variants are not intended to exclude other technical characteristics, additives, components or steps.
- other objects, advantages and features of the invention will be derived partly from the description and partly from the practice of the invention.
- the following examples and figure are provided by way of illustration, and are not intended to be limiting of the present invention.
- FIG. 1 It shows the graphical representation of the induction times of crystallization (in minutes) for a solution of 200 mg / L of calcium and 50 mg / L of oxalate, in synthetic urine, at different concentrations of magnesium and phytate.
- Example 1 Measurement of the crystallization of calcium oxalate in the presence of magnesium and phytate.
- Example 2 Effect of the composition of the invention on wistar rats subjected to a lithogenic diet.
- a group of wistar rats were pretreated with polyphenols extracted from white grape seeds (added to drinking water in concentrations of 200 mg / L) and phytate (1% of the solid diet supplied to animals, in the form of phytin, which is magnesium calcium salt). Subsequently, papillary renal lithiasis was induced by administration of ethylene glycol and the preventive treatment was continued. The antilithic activity of the polyphenol + phytate mixture was evaluated through the calcium content of the kidneys of the animals (extracted at the end of the experiment) and the corresponding histological studies of the renal tissue, by comparison with the corresponding control groups. It was observed that the prophylactic treatment applied reduced renal calcification by 50%.
- Example 3 Effect of the composition of the invention on patients with renal lithiasis problems.
- three pharmaceutical compositions of the present invention are illustrated.
- composition Composition 2. Compound Quantity
- a patient is given orally 200 mg of calcium-magnesium phytate (phytin) together with 200 mg of magnesium citrate and 100 mg of quercitin, twice daily, at breakfast and after dinner.
- the patient's urine inhibitory capacity against calcium oxalate crystallization was increased by 40% with reference to the patient's own urine before ingesting phytate.
- the antioxidant capacity of the urine (potentiometrically evaluated by a platinum electrode) was increased by 15%.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580033945.6A CN106535906B (zh) | 2014-06-25 | 2015-04-14 | 用于治疗或预防肾结石症的含有植酸、镁和多酚的组合物 |
ES15721753T ES2776402T3 (es) | 2014-06-25 | 2015-04-14 | Composición que contiene ácido fítico, magnesio y polifenoles para el tratamiento o la prevención de la litiasis renal |
EP15721753.0A EP3162376B1 (en) | 2014-06-25 | 2015-04-14 | Composition containing phytic acid, magnesium and polyphenols for the treatment or prevention of renal lithiasis |
US15/319,546 US11213535B2 (en) | 2014-06-25 | 2015-04-14 | Composition containing phytic acid, magnesium and polyphenols for the treatment or prevention of renal lithiasis |
KR1020167036615A KR20170015360A (ko) | 2014-06-25 | 2015-04-14 | 신장 결석증의 치료 또는 예방을 위한 피트산, 마그네슘 및 폴리페놀을 함유하는 조성물 |
MX2016016995A MX2016016995A (es) | 2014-06-25 | 2015-04-14 | Composiciones de acido fitico, magnesio y polifenoles y su aplicacion para la prevencion de la litiasis renal oxalocalcica. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201430961A ES2555166B1 (es) | 2014-06-25 | 2014-06-25 | Composiciones de ácido fitico, magnesio y polifenoles y su aplicación para la prevención de la litiasis renal oxalocálcica |
ESP201430961 | 2014-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015197892A1 true WO2015197892A1 (es) | 2015-12-30 |
Family
ID=53175071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2015/070296 WO2015197892A1 (es) | 2014-06-25 | 2015-04-14 | Composición que contiene ácido fítico, magnesio y polifenoles para el tratamiento o la prevención de la litiasis renal |
Country Status (7)
Country | Link |
---|---|
US (1) | US11213535B2 (es) |
EP (1) | EP3162376B1 (es) |
KR (1) | KR20170015360A (es) |
CN (1) | CN106535906B (es) |
ES (2) | ES2555166B1 (es) |
MX (1) | MX2016016995A (es) |
WO (1) | WO2015197892A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018091133A2 (de) | 2016-11-17 | 2018-05-24 | Wind Plus Sonne Gmbh | Nano- und mikropartikel von hexahydroxycyclohexanhexaphosphorsäureestersalzen zur behandlung von kalzinose und als zusatzstoffe für diätetische lebensmittel |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7186506B2 (ja) * | 2018-02-19 | 2022-12-09 | 株式会社ブルボン | 尿路結石症の治療または予防のための赤米糠 |
EP3556398A1 (en) * | 2018-04-16 | 2019-10-23 | Croda Denmark A/S | Phytates for use as a biomolecules delivery or adsorption system |
US20200316002A1 (en) * | 2019-04-03 | 2020-10-08 | Devicare SL | Prevention of urinary tract device encrustation |
CN111418558B (zh) * | 2019-09-22 | 2021-09-28 | 山西大学 | 一种消融代谢性泌尿结石动物模型的构建方法 |
CN111116354B (zh) * | 2019-12-17 | 2022-08-09 | 天津大学 | 没食子酸及其衍生物在控制草酸钙结晶过程的应用 |
CN115444844A (zh) * | 2022-08-30 | 2022-12-09 | 安徽汤谷医药科技有限公司 | 一种药物组合物及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2058025A1 (es) * | 1992-12-04 | 1994-10-16 | Univ De Las Islas Baleares | Aplicacion del acido fitico y/o sus fitatos en los estados patologicos y prepatologicos derivados de la litiasis renal oxalocalcica idiopatica. |
FR2826361A1 (fr) * | 2001-06-26 | 2002-12-27 | Guy Parc | Nouveaux milieux de culture de vegetaux et de cellules, tissus et organes vegetaux renfermant une source d'azote organique et une source d'ester phosphorique |
CN101805236A (zh) * | 2010-05-11 | 2010-08-18 | 蔡瑞琳 | 控释型植酸锌镁硒肥及其制备方法 |
JP2012188685A (ja) * | 2011-03-09 | 2012-10-04 | Nippon Chem Ind Co Ltd | 金属表面処理剤、金属表面処理方法及び表面処理鋼板 |
BRPI1003695A2 (pt) * | 2010-10-25 | 2013-02-19 | De Jesus Henrique Pereira | processo de fabricaÇço de tonico capilar |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5219889A (en) * | 1988-01-05 | 1993-06-15 | The University Of Texas System | Dietary supplementation with potassium magnesium citrate |
ES2068158B1 (es) * | 1993-09-08 | 1995-11-16 | Univ De Las Islas Baleares | Composiciones farmaceuticas de acido fitico o sus derivados y aplicaciones de las mismas. |
CN1111958A (zh) * | 1994-05-16 | 1995-11-22 | 华南师范大学 | 螺旋藻片的制造方法 |
JPH1017447A (ja) * | 1996-06-28 | 1998-01-20 | Lion Corp | 抗歯石剤及び口腔用組成物 |
-
2014
- 2014-06-25 ES ES201430961A patent/ES2555166B1/es active Active
-
2015
- 2015-04-14 CN CN201580033945.6A patent/CN106535906B/zh active Active
- 2015-04-14 EP EP15721753.0A patent/EP3162376B1/en active Active
- 2015-04-14 US US15/319,546 patent/US11213535B2/en active Active
- 2015-04-14 WO PCT/ES2015/070296 patent/WO2015197892A1/es active Application Filing
- 2015-04-14 ES ES15721753T patent/ES2776402T3/es active Active
- 2015-04-14 KR KR1020167036615A patent/KR20170015360A/ko unknown
- 2015-04-14 MX MX2016016995A patent/MX2016016995A/es unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2058025A1 (es) * | 1992-12-04 | 1994-10-16 | Univ De Las Islas Baleares | Aplicacion del acido fitico y/o sus fitatos en los estados patologicos y prepatologicos derivados de la litiasis renal oxalocalcica idiopatica. |
FR2826361A1 (fr) * | 2001-06-26 | 2002-12-27 | Guy Parc | Nouveaux milieux de culture de vegetaux et de cellules, tissus et organes vegetaux renfermant une source d'azote organique et une source d'ester phosphorique |
CN101805236A (zh) * | 2010-05-11 | 2010-08-18 | 蔡瑞琳 | 控释型植酸锌镁硒肥及其制备方法 |
BRPI1003695A2 (pt) * | 2010-10-25 | 2013-02-19 | De Jesus Henrique Pereira | processo de fabricaÇço de tonico capilar |
JP2012188685A (ja) * | 2011-03-09 | 2012-10-04 | Nippon Chem Ind Co Ltd | 金属表面処理剤、金属表面処理方法及び表面処理鋼板 |
Non-Patent Citations (12)
Title |
---|
AMENGUAL-CLADERA EMILIA ET AL: "Phytotherapy in a rat model of hyperoxaluria: the antioxidant effects of quercetin involve serum paraoxonase 1 activation", EXPERIMENTAL BIOLOGY AND MEDICINE, SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, US, vol. 236, no. 10, 1 October 2011 (2011-10-01), pages 1133 - 1138, XP008176654, ISSN: 1535-3702, DOI: 10.1258/EBM.2011.011090 * |
DATABASE WPI Week 201074, Derwent World Patents Index; AN 2010-L41320, XP002741092 * |
DATABASE WPI Week 201373, Derwent World Patents Index; AN 2013-L99911, XP002741091 * |
F GRASES; A COSTA-BAUZA; RM PRIETO; A CONTE; A SERVERA, BMC UROL, vol. 13, 2013, pages 14 |
F GRASES; RM PRIETO; P SANCHIS; C SAUS; T DE FRANCISCO, J NEPHROL, vol. 21, no. 5, 2008, pages 768 - 75 |
F. GRASES; RM PRIETO; I GOMILA; P SANCHIS; A COSTA-BAUZA, UROL RES, vol. 37, no. 1, 2009, pages 35 - 40 |
FELIX GRASES ET AL: "Phytotherapy and renal stones: the role of antioxidants. A pilot study in Wistar rats", UROLOGICAL RESEARCH ; A JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION IN UROLITHIASIS AND RELATED AREAS, SPRINGER, BERLIN, DE, vol. 37, no. 1, 10 December 2008 (2008-12-10), pages 35 - 40, XP019704612, ISSN: 1434-0879 * |
GRASES FELIX ET AL: "Phytate acts as an inhibitor in formation of renalcalculi", FRONTIERS IN BIOSCIENCE, FRONTIERS IN BIOSCIENCE, ALBERTSON, NY, US, vol. 12, 1 January 2007 (2007-01-01), pages 2580 - 2587, XP008176574, ISSN: 1093-9946, DOI: 10.2741/2256 * |
JOHANSSON G ET AL: "Effects of magnesiumhydroxide in renalstone disease", JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, AMERICAN COLLEGE OF NUTRION, WILMINGTON, NC, US, vol. 1, no. 2, 1 January 1982 (1982-01-01), pages 179 - 185, XP008176653, ISSN: 0731-5724, [retrieved on 20130902], DOI: 10.1080/07315724.1982.10718985 * |
R M FORBES ET AL: "Effects of dietary phytate, calcium and magnesium levels on zinc bioavailability to rats", THE JOURNAL OF NUTRITION, 1 August 1984 (1984-08-01), UNITED STATES, pages 1421, XP055195078, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/6747725> * |
VITALI D ET AL: "Bioaccessibility of Ca, Mg, Mn and Cu from whole grain tea-biscuits: Impact of proteins, phytic acid and polyphenols", FOOD CHEMISTRY, ELSEVIER LTD, NL, vol. 110, no. 1, 1 September 2008 (2008-09-01), pages 62 - 68, XP022589877, ISSN: 0308-8146, [retrieved on 20080205], DOI: 10.1016/J.FOODCHEM.2008.01.056 * |
WU N ET AL: "Effects of magnesiumcitrate and phytin on reducing urinary calcium excretion in rats", WORLD JOURNAL OF UROLOGY, SPRINGER INTERNATIONAL, DE, vol. 12, no. 6, 1 December 1994 (1994-12-01), pages 323 - 328, XP008176655, ISSN: 0724-4983, DOI: 10.1007/BF00184113 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018091133A2 (de) | 2016-11-17 | 2018-05-24 | Wind Plus Sonne Gmbh | Nano- und mikropartikel von hexahydroxycyclohexanhexaphosphorsäureestersalzen zur behandlung von kalzinose und als zusatzstoffe für diätetische lebensmittel |
Also Published As
Publication number | Publication date |
---|---|
CN106535906B (zh) | 2020-04-03 |
MX2016016995A (es) | 2017-08-21 |
KR20170015360A (ko) | 2017-02-08 |
US11213535B2 (en) | 2022-01-04 |
CN106535906A (zh) | 2017-03-22 |
ES2555166A1 (es) | 2015-12-29 |
ES2776402T3 (es) | 2020-07-30 |
EP3162376B1 (en) | 2019-12-18 |
ES2555166B1 (es) | 2016-10-04 |
EP3162376A1 (en) | 2017-05-03 |
US20170128469A1 (en) | 2017-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2555166B1 (es) | Composiciones de ácido fitico, magnesio y polifenoles y su aplicación para la prevención de la litiasis renal oxalocálcica | |
EP3130336A1 (en) | Food and/or nutraceutical composition containing pea | |
Salman et al. | Protective effect of proanthocyanidins on nephrotoxicity induced by antitumor dose of cisplatin in ehrlich solid tumor-bearing mice | |
WO2004037015A1 (en) | Antioxidative Compositions | |
AU2003282829B2 (en) | Antioxidative Compositions | |
CN105935364B (zh) | 用于预防或治疗非酒精性肝病的包含人参皂苷f2的组合物 | |
ES2773628T3 (es) | Combinación de un acidificante urinario y un inhibidor de la cristalización del fosfato cálcico para el tratamiento o prevención de la litiasis renal | |
WO2018039755A1 (pt) | Formulação farmacêutica a base de zinco e quercetina para a produção de medicação antiviral eficaz para dengue e zika | |
ES2280136B1 (es) | Asociacion a dosis fija de fitato y zinc. | |
Gupta et al. | Kidney stones: Mechanism of formation, pathogenesis and possible treatments | |
JP6126592B2 (ja) | 前立腺癌の治療又は予防用のブロッコリー種子抽出物含有組成物 | |
ES2397085T3 (es) | Procedimientos y combinaciones de polifenol-coxib | |
JP6290896B2 (ja) | 植物性フェノール、及び好酸球性食道炎の治療若しくは予防におけるその使用 | |
EP2241198A1 (en) | Mucositis prevention supplement and treatment | |
ES2729863T3 (es) | Combinaciones de un agente basificante urinario y un inhibidor de cristalización del ácido úrico para el tratamiento o prevención de la litiasis renal | |
AU2017347778A1 (en) | Delaying latency to seizure by combinations of ketone supplements | |
ES2552706A1 (es) | La teobromina y sus derivados para el tratamiento o prevención de la litiasis renal | |
ES2750632T3 (es) | Utilización de un extracto particular de propóleo para luchar contra los efectos secundarios de quimioterapias | |
Frias | Design, development and characterization of innovative lipid nanocarrier-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation | |
BG1474U1 (bg) | Хранителна добавка, повишаваща защитата на епитела на долните пикочни пътища от повторни инфекции |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15721753 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15319546 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/016995 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 20167036615 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015721753 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015721753 Country of ref document: EP |